The number of CD4+CD25+FoxP3+Tregs in peripheral blood is decreased during the active stage of anti-AChR antibody-positive MG and becomes higher with immunotherapy, implying that decreased number of Tregs may lead to immune disorders (44). This evidence concerns the gene CD4 and myasthenia gravis.